NasdaqCM - Nasdaq Real Time Price USD

BioLineRx Ltd. (BLRX)

0.6130

-0.0238

(-3.74%)

At close: 4:00 PM EDT

0.6383

+0.03

(+4.13%)

After hours: 4:56 PM EDT

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a poster presentation on apheresis center efficiency and CXCR4 antagonists including APHEXDA (motixafortide) in patients with multiple myeloma. The poster will be presented at the American Society for Apheresis (ASFA) 2024 Annual Meeting, taking place April 17-19, 2024, in Las Vegas, Nevada.

PR Newswire 7 days ago

BLRX
-3.74%
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has drawn-down the second tranche of $20 million under its previously announced $40 million non-dilutive debt financing agreement with funds and accounts managed by BlackRock.

PR Newswire 14 days ago

BLRX
-3.74%
BioLineRx Announces $6 Million Registered Direct Offering

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 7,500,000 of the Company's American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 7,500,000 ADSs, at a combined purchase price of

PR Newswire 23 days ago

BLRX
-3.74%
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript March 26, 2024 BioLineRx Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Fourth Quarter and Full Year 2023 Financial […]

Insider Monkey 28 days ago

BLRX
-3.74%
BLRX: First Aphexda Sales Recognized

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT Since the 3Q:23 report in November, BioLineRx Ltd. (NASDAQ:BLRX) has been focused on Aphexda commercialization following drug approval in September 2023. Since then, two other trials evaluating motixafortide have dosed first patients. One was the gene therapy trial in collaboration with the Washington University School of

Zacks Small Cap Research 28 days ago

BLRX
-3.74%
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its financial results for the year ended December 31, 2023, and provided recent corporate and portfolio updates.

PR Newswire 29 days ago

BLRX
-3.74%
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced it will release its audited financial results for the year ended December 31, 2023 on Tuesday, March 26, 2024, before the U.S. markets open.

PR Newswire last month

BLRX
-3.74%
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent, "Process for Manufacturing Peptide," covering a method of manufacturing motixafortide (BL-8040) that is suitable for large scale production.

PR Newswire last month

BLRX
-3.74%
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that the first patient has been dosed in the randomized CheMo4METPANC Phase 2 combination clinical trial evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic c

PR Newswire last month

BLRX
-3.74%
BLRX: Poster Presentations

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT Subgroup Analyses of Genesis Trial Data at ASTCT & CIBMTR Washington University School of Medicine’s Zachary Crees, MD and BioLineRx’ (NASDAQ:BLRX) Ella Sorani, PhD descended on San Antonio, Texas last week to participate in poster presentations for the Transplantation & Cellular Therapy Meetings of the American

Zacks Small Cap Research last month

BLRX
-3.74%
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond

In almost every situation, investors should stay away from penny stocks. They’re extremely speculative and they tend to facilitate delusions of grandeur. To be sure, there’s nothing wrong with hope. But hope shouldn’t be a substitute for sound research and due diligence. Still, it’s also possible – in some limited sense – that you miss 100% of the shots you don’t take. Granted, I’ve got to be careful with this statement. If you take the shots, you’re more likely to miss than hit and those misses

InvestorPlace last month

TNXP

BLRX
-3.74%
KZR
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that new post-hoc subgroup analyses and pharmacodynamic data will be presented on APHEXDA® (motixafortide) for CD34+ hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®

PR Newswire 2 months ago

BLRX
-3.74%
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating motixafortide as monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in sickle cell disease (SCD). The proof-of-concept trial, which plans to enroll five patients diagnosed with SCD, i

PR Newswire 4 months ago

BLRX
-3.74%
BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript

BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript November 20, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Third Quarter 2023 Financial Results Conference Call. All participants are presently in a listen-only mode. Following management’s formal presentation, instructions will be given for the question-and-answer session. [Operator Instructions] I would […]

Insider Monkey 5 months ago

BLRX
-3.74%
BLRX: A Series of Fortunate Events

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT 3Q:23 Operational and Financial Results Activity stepped up substantially following BioLineRx Ltd.’s (NASDAQ:BLRX) report of second quarter results. Shortly after the report, the FDA approved Aphexda and BioLineRx announced the closing of the Asia deal with Gloria Biosciences. Data for the collaboration with Columbia

Zacks Small Cap Research 5 months ago

BLRX
-3.74%
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the third quarter ended September 30, 2023, and provided corporate and portfolio updates.

PR Newswire 5 months ago

BLRX
-3.74%
BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced it will release its unaudited financial results for the quarter ended September 30, 2023 on Monday, November 20, 2023, before the U.S. markets open.

PR Newswire 5 months ago

BLRX
-3.74%
3 Tech Stocks That Wall Street Loves More Than Nvidia

The future of the U.S. economy appears to be at a pivotal juncture as the Federal Reserve maintains interest rates at a 22-year high, with the possibility of further tightening on the horizon. Despite strong economic indicators, including a robust labor market and faster-than-expected GDP growth, the central bank remains cautious about achieving its 2% inflation target. Fed Chair Jay Powell emphasizes the need for monetary policy to curb inflation, but also hints at proceeding “carefully” with f

InvestorPlace 5 months ago

AVGO

ZM

BLRX
-3.74%
BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures

M.S.Q. Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia.

CNW Group 5 months ago

BLRX
-3.74%
3 Top Penny Stocks to Make You a Millionaire in 5 Years

In general, penny stock investing is all about quick gains. Investors in this high-risk world usually are in it for a quick buck. Those who win tend to win big. Less often, investors buy penny stocks with a buy-and-hold mentality. Buying and holding is precisely what we’re advocating for in this case. The companies and shares discussed below, if held for a few years, have all the potential to produce large returns for investors. The firms discussed benefits from trends that appear likely to cont

InvestorPlace 5 months ago

BLRX
-3.74%

Performance Overview

Return	BLRX	TA-125
YTD	-60.96%	+4.58%
1-Year	-45.75%	+14.53%
3-Year	-78.72%	+15.53%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioLineRx Ltd. (BLRX)

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

BioLineRx Announces $6 Million Registered Direct Offering

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript

BLRX: First Aphexda Sales Recognized

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

BLRX: Poster Presentations

3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript

BLRX: A Series of Fortunate Events

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

3 Tech Stocks That Wall Street Loves More Than Nvidia

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures

3 Top Penny Stocks to Make You a Millionaire in 5 Years

Performance Overview